Welcome to our dedicated page for Compass Therapeutics news (Ticker: CMPX), a resource for investors and traders seeking the latest updates and insights on Compass Therapeutics stock.
Compass Therapeutics Inc. (Nasdaq: CMPX) advances novel antibody therapies targeting cancer's complex biology through its clinical-stage pipeline. This dedicated news center provides investors and researchers with essential updates on oncology developments, trial milestones, and scientific breakthroughs.
Access timely reports on bispecific antibody programs, including Tovecimig (CTX-009) for biliary tract cancers and CTX-471's CD137 agonist mechanism. Track regulatory progress across multiple indications and discover partnership announcements leveraging Compass' StitchMabs platform technology.
Our curated news collection serves as your primary source for:
- Phase 1-3 clinical trial updates
- FDA submissions and international regulatory milestones
- Peer-reviewed research publications
- Strategic collaborations in immuno-oncology
Bookmark this page for real-time insights into Compass' work on angiogenesis modulation and tumor microenvironment targeting. Monitor biomarker-driven developments that could shape next-generation cancer treatments.
Compass Therapeutics, Inc. (CMPX) announced a private investment in public equity (PIPE) financing, selling 25 million shares at $3.21 each, totaling approximately $80 million. The financing, led by Enavate Sciences and other institutional investors, is expected to close by November 8, 2022. Funds will advance their clinical pipeline, including CTX-009, CTX-471, and CTX-8371, extending the company's cash runway into 2026. The securities have not been registered under the Securities Act but will be subject to a registration rights agreement for resale.
Compass Therapeutics (Nasdaq: CMPX) announced a clinical trial collaboration with Merck to evaluate its monoclonal antibody CTX-471 in combination with KEYTRUDA® for treating advanced cancers post anti-PD-1 therapy. The Phase 1b trial will enroll patients with various cancer types and assess safety, pharmacokinetics, and clinical activity. Initial results from earlier trials showed partial responses in patients. This collaboration marks a significant advancement in cancer immunotherapy.
Compass Therapeutics (Nasdaq: CMPX) announced its participation in the 24th Annual H.C. Wainwright Global Investment Conference in New York City, scheduled for September 12 – 14, 2022. The company's presentation is set for September 13, 2022, at 2:30 PM EDT. A webcast of the presentation will be available and archived on their Events page for 90 days.
Compass Therapeutics, Inc. (Nasdaq: CMPX) will present at the 2022 Wedbush PacGrow Healthcare Conference, scheduled virtually for August 9-10, 2022. The presentation is set for August 9 at 4:05 pm ET. Interested parties can access the webcast here, and it will be available for replay for 90 days on Compass’s Events page.
Compass Therapeutics focuses on developing antibody-based therapeutics aimed at treating cancer by targeting critical biological pathways.
Compass Therapeutics (CMPX) reported Q2 2022 results with a net loss of $8.5M ($0.08/share), down from $55.8M ($1.07/share) in Q2 2021. Cash and marketable securities totaled $132M, extending their runway into H2 2024. The company is set to initiate a Phase 2/3 trial for CTX-009 in biliary tract cancer (BTC) and a Phase 2 trial for advanced colorectal cancer (CRC) by Q4 2022. Additionally, CTX-471 continues to show efficacy in mesothelioma patients, with four reported partial responses. R&D expenses rose to $5.9M from $2.9M, while G&A expenses increased to $3.1M from $2.2M, reflecting ongoing operational growth.
Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company, will present at the 2022 Jefferies Global Healthcare Conference on June 9, 2022, at 8:00 am ET in New York City. The presentation will focus on the company's proprietary antibody-based cancer therapeutics. It will be available for live streaming and archived for 90 days on their website. Compass Therapeutics aims to advance innovative therapies targeting critical biological pathways in oncology.
Compass Therapeutics, a clinical-stage biopharmaceutical company focused on antibody-based cancer treatments, announced that CEO Thomas J. Schuetz will present at the 2022 H.C. Wainwright Global Investment Conference from May 23-26, 2022. The webinar will be available on-demand starting May 24, 2022, at 7:00 a.m. ET, and can be accessed through their website. Compass Therapeutics is dedicated to developing therapies targeting angiogenesis and immune response mechanisms to combat tumors, with a pipeline aimed at advancing multiple product candidates.
Compass Therapeutics, Inc. (CMPX) announced the FDA's approval of the investigational new drug application for CTX-009, allowing an expansion to a global Phase 2 study in biliary tract cancer. Interim data indicated a 42% overall response rate (ORR) and a 92% clinical benefit rate (CBR) among the first 24 patients. The CTX-471 Phase 1b study reported 3 partial responses. As of March 31, 2022, the company had $136.4 million in cash, anticipated to fund operations into late 2024, with a reduced net loss of $7.2 million for Q1 2022, compared to $7.3 million in Q1 2021.
Compass Therapeutics, a clinical-stage biopharmaceutical company focused on antibody-based cancer treatments, announced that CEO Thomas J. Schuetz will present at the Bank of America Securities 2022 Healthcare Conference. The event is set for May 12, 2022, at 11:20 AM PT in Las Vegas. The presentation will be available live and replayed 24 hours post-event on the company's website. Compass is dedicated to developing therapies targeting critical biological pathways essential for effective anti-tumor responses.
Compass Therapeutics (Nasdaq: CMPX) announced interim results from its Phase 2 study of CTX-009, revealing a 42% overall response rate (ORR) based on 10 partial responses among 24 patients with biliary tract cancers. The clinical benefit rate reached 92%, with most patients exhibiting stable disease. The drug was well tolerated, aligning with Phase 1 findings. Compass plans to commence the second stage of the study in the U.S. in Q3 2022. The data suggest CTX-009 may offer a new treatment avenue for patients with limited options.
